Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
BCT Stock Chart & Stats
C$10.64
-C$0.02(-3.08%)
At close: 4:00 PM EST
C$10.64
-C$0.02(-3.08%)
Day’s Range― - ―
52-Week RangeC$4.95 - C$135.00
Previous CloseN/A
Volume105.15K
Average Volume (3M)3.11K
Market Cap
C$42.78M
Enterprise Value-C$32.32M
Total Cash (Recent Filing)C$40.49M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding7,250,487
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength (no Debt)Zero reported total debt and an equity position that recovered from negative to positive in 2025 and TTM materially lower structural leverage risk. This durable financial footing improves solvency resilience, preserves strategic optionality for R&D funding, and reduces near-term default/refinancing pressure.
Focused Immuno-oncology PipelineA clear, focused business model centered on immuno-oncology (Bria-IMT and combinations) provides a durable strategic identity and concentration of scientific expertise. This focus supports efficient R&D resource allocation, clearer regulatory paths for lead assets, and potential lasting competitive differentiation if clinical milestones are met.
Improving FCF Trend Vs Prior PeriodAlthough free cash flow remains negative in absolute terms, the positive TTM growth versus the prior period signals improving operational cash dynamics. A sustained improvement trend would reduce reliance on immediate financing, extend runway, and reflect better execution of development and spending discipline over the medium term.
Bears Say
No Revenue / Negative Gross ProfitThe absence of revenue and persistent negative gross profit is a structural constraint for a sustainable business model. Without commercial revenues, the company must rely on external capital to fund R&D, leaving long-term viability tied to clinical success and future fundraising rather than internally generated cash flow.
High Cash Burn And Negative Operating Cash FlowA TTM free cash flow near -$37M and consistently negative operating cash flow create persistent funding risk. Structurally high cash burn compresses runway, increases the probability of dilutive financings, and constrains the ability to invest flexibly in additional trials or partnerships without securing new capital.
Widening Net Losses / Negative ReturnsMaterially widening net losses (TTM ~45.8M) and very negative return on equity indicate the capital base is not producing returns. Persistently expanding losses erode investor capital over time, raise governance and strategic pressure, and make sustaining long-term development programs more difficult without substantial new funding.
BriaCell Therapeutics News
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$4.95 and its highest was C$135.00 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$42.78M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Jun 17, 2026 which is in 96 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Mar 10, 2026. The company reported -C$3.575 earnings per share for the quarter, missing the consensus estimate of N/A by -C$3.575.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 7,250,487 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$3.575 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.914%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―